Defender Capital LLC. Increases Holdings in Lineage Cell Therapeutics, Inc. $LCTX

Key Points

• Defender Capital LLC increased its stake in Lineage Cell Therapeutics by 7.5% during the 2nd quarter, holding 6,785,177 shares valued at approximately $6.16 million.
• A number of other investors, including Charles Schwab Investment Management and Red Crane Wealth Management, also increased their positions in Lineage Cell Therapeutics during the first quarter.
• Lineage Cell Therapeutics has a current consensus rating of "Buy" from analysts, with an average price target of $4.25, significantly higher than its current trading price of $1.77.

Defender Capital LLC. grew its holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 7.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,785,177 shares of the company's stock after acquiring an additional 474,304 shares during the period. Lineage Cell Therapeutics comprises about 2.1% of Defender Capital LLC.'s investment portfolio, making the stock its 12th biggest position. Defender Capital LLC. owned about 2.97% of Lineage Cell Therapeutics worth $6,157,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in LCTX. ORG Partners LLC purchased a new position in shares of Lineage Cell Therapeutics in the first quarter valued at about $47,000. Charles Schwab Investment Management Inc. lifted its position in shares of Lineage Cell Therapeutics by 20.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 503,193 shares of the company's stock valued at $227,000 after acquiring an additional 86,970 shares in the last quarter. Red Crane Wealth Management LLC lifted its position in shares of Lineage Cell Therapeutics by 45.8% in the first quarter. Red Crane Wealth Management LLC now owns 495,996 shares of the company's stock valued at $224,000 after acquiring an additional 155,760 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Lineage Cell Therapeutics in the first quarter worth about $233,000. Finally, Cookson Peirce & Co. Inc. bought a new position in Lineage Cell Therapeutics during the first quarter valued at approximately $113,000. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Price Performance

Shares of NYSEAMERICAN LCTX opened at $1.77 on Tuesday. The business's 50 day moving average is $1.36 and its two-hundred day moving average is $0.93. Lineage Cell Therapeutics, Inc. has a 1-year low of $0.37 and a 1-year high of $1.83. The stock has a market capitalization of $404.20 million, a P/E ratio of -9.83 and a beta of 1.77.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on LCTX. HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Monday, June 23rd. D. Boral Capital restated a "buy" rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Wednesday, August 27th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Lineage Cell Therapeutics presently has a consensus rating of "Buy" and an average price target of $4.25.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Want to see what other hedge funds are holding LCTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.